1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methyl-1H-indole-4-carbonitrile | 1542705-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methyl-1H-indole-4-carbonitrile
• 英文别名: 1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methylindole-4-carbonitrile；1-[4-(Benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methylindole-4-carbonitrile
• CAS: 1542705-59-8
• 化学式: C₂₅H₂₃N₅
• 分子量: 393.491
• InChiKey: JGBYAFQJKJUPAR-UHFFFAOYSA-N

物化性质

• 沸点：
  679.0±65.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  66.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methyl-1H-indole-4-carbonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以59%的产率得到2-(4-(aminomethyl)-2-methyl-1H-indol-1-yl)-N-benzyl-5,6,7,8-tetrahydroquinazolin-4-amine
  参考文献：
  名称：

  [EN] FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
  [FR] PYRIMIDINES FUSIONNÉES EN TANT QU'INHIBITEURS DU COMPLEXE P97

  摘要：

  本发明揭示了一种融合嘧啶化合物，其具有饱和、不饱和或芳香性A环与嘧啶环融合，并在嘧啶环的2位具有复杂的取代基，在4位具有取代胺基，以及在其他位置可选地具有取代的脂肪族、功能性和/或芳香性组分的嘧啶环和A环。这些化合物是包含p97的AAA蛋白酶复合物的抑制剂，是治疗与p97生物活性相关的疾病如癌症的有效药物。

  公开号：

  WO2014015291A1
• 作为产物：
  描述：

  4-溴吲哚 在 1,1'-双(二苯基膦)二茂铁 、 tris-(dibenzylideneacetone)dipalladium(0) 、 正丁基锂 、 sodium hydride 、 caesium carbonate 、 sodium hydroxide 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N-甲基吡咯烷酮 、 乙醇 、 水 为溶剂， 反应 18.0h， 生成 1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methyl-1H-indole-4-carbonitrile
  参考文献：
  名称：

  Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

  摘要：

  The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin proteasome system (ups) mediated protein degradation, endoplasmic reticulum-associated degradation (BRAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-6083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell, death. In tumor bearing mice, oral administration of 71 causes rapid accumulation Of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to Sustained antitumor activity in in vivo, xenograft models of both solid and hematological tumors. 71 has been taken into phase I clinical trials in patients with multiple myeloma and solid tumors.

  DOI：

  10.1021/acs.jmedchem.5b01346

文献信息

• FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX
  申请人：Cleave Biosciences, Inc.

  公开号：US20170258795A1

  公开（公告）日：2017-09-14

  Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

  本发明公开了一种融合嘧啶化合物，其具有饱和，不饱和或芳香性A环融合到嘧啶环上，并在嘧啶环的2位位置具有复杂的取代基和取代胺在嘧啶环的4位位置，以及可选的脂肪烷基，功能性和/或芳香基组分取代在嘧啶环和A环的其他位置。这些化合物是AAA蛋白酶复合物的抑制剂，包含p97，并且是用于治疗与p97生物活性相关的疾病的有效药物，例如癌症。
• Fused pyrimidines as inhibitors of P97 complex
  申请人：Cleave Biosciences, Inc.

  公开号：US10010554B2

  公开（公告）日：2018-07-03

  Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

  本发明公开了具有与嘧啶环融合的饱和、不饱和或芳香 A 环的融合嘧啶化合物，该化合物在嘧啶环的 2 位具有复合取代基，在 4 位具有取代胺，并在嘧啶环和 A 环的其他位置具有任选取代的脂肪族、官能团和/或芳香族成分。这些化合物是含有 p97 的 AAA 蛋白酶体复合物的抑制剂，是治疗与 p97 生物活性有关的疾病（如癌症）的有效药物。
• FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
  申请人：Cleave Biosciences, Inc.

  公开号：EP2875018B1

  公开（公告）日：2018-02-14
• FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97
  申请人：Zhou Han-Jie

  公开号：US20140024661A1

  公开（公告）日：2014-01-23

  A group of fused two ring pyrimidine compounds having a heterocycles substituent at the 2 position and a substituted amine at the 4 position as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine and other ring are disclosed. In addition a group of quinazoline compounds having similar substituents at the 2 and 4 positions as well as at other positions are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity.
• US9062026B2
  申请人：——

  公开号：US9062026B2

  公开（公告）日：2015-06-23